title: Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience.
authors.affiliation: Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044; Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 100038, China.
authors.forename: Tian-Jiao
authors.initials: TJ
authors.lastname: Guo
authors.affiliation: Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
authors.affiliation: Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Wen
authors.affiliation: Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D000069286:Bortezomib